Drug Type Small molecule drug |
Synonyms DNX-114 |
Target |
Action inhibitors |
Mechanism TNF inhibitors(Tumor necrosis factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ankylosing Spondylitis | Preclinical | United States | 31 Aug 2022 | |
| Arthritis, Psoriatic | Preclinical | United States | 31 Aug 2022 | |
| Juvenile Idiopathic Arthritis | Preclinical | United States | 31 Aug 2022 | |
| Plaque psoriasis | Preclinical | United States | 31 Aug 2022 | |
| Rheumatoid Arthritis | Preclinical | United States | 31 Aug 2022 |





